ArticleEuropean journal of histochemistry : EJH2026
Cryptotanshinone alleviates DSS-induced colitis in mouse by regulating the balance of Treg/Th17 cells and M1 macrophage activation.
Article in European journal of histochemistry : EJH, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammatory bowel disease (IBD) including ulcerative colitis (UC) and Crohn's disease has become a global disease in the 21st century, with increasing incidence rates in almost every industrialized country. Previous studies have suggested that the traditional Chinese medicine herb, cryptotanshinone (CTN), a major liposoluble extract of Salvia miltiorrhiza, alleviates the symptoms of experimental colitis in vitro and in vivo. However, the mechanisms underlying the protective effects of CTN against IBD remain exclusive. The present study found that CTN reversed lipopolysaccharide-induced inflammation in human colon epithelial cells (HIEC-6) by inhibiting the NF-κB pathway. In addition, CTN alleviated dextran sulfate sodium (DSS)-induced inflammatory bowel disease in mice by regulating the balance of TH17/Treg cells. CTN also exerted its role by inhibiting the polarization of M1 macrophages in mice with DSS-induced colitis. Of note, the effects of CTN on these immune cells may be mediated via changes in the levels of TNF-α and IL-6 directly in mice. Taken together, these findings may provide new insight regarding the therapeutic potential of CTN for UC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.